Showing 7271-7280 of 9550 results for "".
- FDA Approves PMA Supplement for MelaFind from STRATA Scienceshttps://practicaldermatology.com/news/fda-accepts-pma-for-melafind-from-strata-sciences/2458644/The FDA has approved STRATA Skin Sciences, Inc.’s PMA supplement for the MelaFind System. The FDA approved MelaFind’s use of the “classifier score data”, a quantitative result derived by the MelaFind System that can be beneficially used in conjunction with the previously a
- New Research Suggests Why PD-1 Blockers Don't Work for All Melanoma Patientshttps://practicaldermatology.com/news/new-research-suggests-why-pd-1-blockers-dont-work-for-all-melanoma-patients/2458645/Immunotherapy using anti-PD-1 antibodies has been a game change for metastatic melanoma patients, but 60 to 70 percent of patients’ melanoma tumors are resistant to the anti-PD-1 antibodies. Now new research out of UCLA suggests that patterns of gene
- Revance Therapeutics Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Developmenthttps://practicaldermatology.com/news/revance-therapeutics-appoints-roman-g-rubio-md-mba-as-senior-vice-president-of-clinical-development/2458649/Revance Therapeutics, Inc. has named Roman G. Rubio, MD, MBA Senior Vice President of Clinical Development. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company’s clinical development team, focusing on further accelerating the advancement of Reva
- Smartphone Microscopes May Aid Skin Cancer Detection in Developing Worldhttps://practicaldermatology.com/news/smartphone-microscopes-may-aid-skin-cancer-detection-in-developing-world/2458648/Smartphone microscopes may improve the detection of skin cancer in developing countries, according to a study in the Archives of Pathology & Laboratory Medicine. Researchers from The
- APP® Membership Now Has More Rewards: Three Syneron Candela Platformshttps://practicaldermatology.com/news/app-membership-now-has-more-rewards-three-syneron-candela-platforms/2458655/Syneron Medical Ltd. and Allergan plc are joining forces to offer three of Syneron Candela's body sculpting and skincare platforms to members of Allergan Partner Privileges® (APP®</
- Cipher Pharmaceuticals Appoints New President and General Manager of US Businesshttps://practicaldermatology.com/news/cipher-pharmaceuticals-appoints-new-president-and-general-manager-of-us-business/2458662/Cipher Pharmaceuticals Inc. named Ralph Bohrer as President and General Manager of its US subsidiary. Mr. Bohrer is a seasoned pharmaceutical executive with 30 years of experience in sales and marketing leadership for growing dermatology companies. Prior to
- Syneron Candela Introducing New Technologies at the 2016 AAD Annual Meetinghttps://practicaldermatology.com/news/syneron-candela-introducing-new-technologies-at-the-2016-aad-annual-meeting/2458664/Syneron Medical Ltd., is launching three new products during the 2016 American Academy of Dermatology (AAD) meeting in Washington, DC. The launches include the new CO2RE Intima sy
- Cool Change: New CoolSculpting Apps Slash Treatment Timehttps://practicaldermatology.com/news/cool-change-new-coolsculpting-apps-slash-treatment-time/2458666/ZELTIQ® Aesthetics, Inc. is welcoming a new family of applicators called CoolAdvantage™ at the American Academy of Dermatology Annual Meeting in Washington, D.C. The CoolAdvantage applicator delivers CoolSculpting
- Vitiligo Working Group Launches Public Awareness Campaignhttps://practicaldermatology.com/news/vitiligo-working-group-launches-public-awareness-campaign/2458665/The Vitiligo Working Group is drawing attention to the many faces of vitiligo with a new public awareness campaign. This initiative rolls out at the 74th Annual Meeting of the American Academy of Dermatology (AAD) in Washington, DC.
- Provectus Biopharmaceuticals Announces Leadership Changeshttps://practicaldermatology.com/news/provectus-biopharmaceuticals-announces-leadership-changes/2458674/Provectus Biopharmaceuticals, Inc. detailed several leadership changes following the resignation of one of its Co-Founders and its Chairman and CEO, H. Craig Dees, PhD. The Provectus Board of Directors accepted the resignation of Dr. Dees, which he submitted due to personal and health reasons, in